FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022709201> ?p ?o ?g. }

• W2022709201 endingPage "2406" @default.
• W2022709201 startingPage "2399" @default.
• W2022709201 abstract "Objective: Hepatitis B virus (HBV) reactivation is a well-known complication in cancer patients receiving cytotoxic chemotherapy, resulting in varying degrees of liver damage. The objective of this study was to investigate the efficacy of lamivudine for the prevention of HBV reactivation in non-Hodgkin's lymphoma (NHL) patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). Research design and methods: Thirty-two patients with NHL who were HBV surface antigen (HBsAg)-positive were enrolled in this pilot study. They were divided into two groups: 20 patients received prophylactic oral lamivudine 100 mg/day before, and until at least 6 months after transplantation. The historical control group comprised 12 patients who received high-dose chemotherapy and AHSCT without lamivudine. The incidence and severity of hepatitis due to HBV reactivation, as well as other adverse clinical outcomes, were compared between the two groups. Results: Most baseline clinical characteristics were similar in the two groups, except for HBV e-antigen (HBeAg)-positive status (85% in the lamivudine group vs 33.3% in the control group, p = 0.006) and the type of AHSCT. There was a lower incidence of hepatitis due to HBV reactivation in the lamivudine group than in the control group (10 vs 50%, p = 0.030), less severe hepatitis (0 vs 25%, p = 0.009), and lower mortality (0 vs 25%, p = 0.236). An HBV variant with tyrosine methionine aspartate aspartate (YMDD) mutation was detected in one patient in the lamivudine group (5%) after administration of lamivudine for 9 months. No significant adverse events were associated with the use of prophylactic lamivudine, and hematopoietic reconstitution was not affected by the intervention. Conclusions: Prophylactic lamivudine may reduce the incidence and severity of chemotherapy-related HBV reactivation and hepatitis-related mortality in HBsAg-positive NHL patients receiving high-dose chemotherapy and AHSCT. Additional randomized, multicenter trials are warranted." @default.
• W2022709201 created "2016-06-24" @default.
• W2022709201 creator A5003905939 @default.
• W2022709201 creator A5006987355 @default.
• W2022709201 creator A5012693175 @default.
• W2022709201 creator A5029398579 @default.
• W2022709201 creator A5034618391 @default.
• W2022709201 creator A5050833679 @default.
• W2022709201 creator A5077996407 @default.
• W2022709201 date "2009-09-17" @default.
• W2022709201 modified "2023-10-06" @default.
• W2022709201 title "Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience" @default.
• W2022709201 cites W1818726713 @default.
• W2022709201 cites W1966282055 @default.
• W2022709201 cites W1974663430 @default.
• W2022709201 cites W1983039036 @default.
• W2022709201 cites W1996846115 @default.
• W2022709201 cites W1997353354 @default.
• W2022709201 cites W2015887202 @default.
• W2022709201 cites W2033597506 @default.
• W2022709201 cites W2042653073 @default.
• W2022709201 cites W2046386392 @default.
• W2022709201 cites W2064209815 @default.
• W2022709201 cites W2071291950 @default.
• W2022709201 cites W2083101441 @default.
• W2022709201 cites W2083629462 @default.
• W2022709201 cites W2085997970 @default.
• W2022709201 cites W2091626340 @default.
• W2022709201 cites W2101159020 @default.
• W2022709201 cites W2106174199 @default.
• W2022709201 cites W2117251229 @default.
• W2022709201 cites W2131508403 @default.
• W2022709201 cites W2137512984 @default.
• W2022709201 cites W2138955583 @default.
• W2022709201 cites W2156015715 @default.
• W2022709201 cites W2164785014 @default.
• W2022709201 cites W2274356580 @default.
• W2022709201 cites W2323719395 @default.
• W2022709201 cites W2338794667 @default.
• W2022709201 cites W24404253 @default.
• W2022709201 doi "https://doi.org/10.1517/14656560903251710" @default.
• W2022709201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19761353" @default.
• W2022709201 hasPublicationYear "2009" @default.
• W2022709201 type Work @default.
• W2022709201 sameAs 2022709201 @default.
• W2022709201 citedByCount "17" @default.
• W2022709201 countsByYear W20227092012012 @default.
• W2022709201 countsByYear W20227092012014 @default.
• W2022709201 countsByYear W20227092012015 @default.
• W2022709201 countsByYear W20227092012016 @default.
• W2022709201 countsByYear W20227092012017 @default.
• W2022709201 countsByYear W20227092012018 @default.
• W2022709201 countsByYear W20227092012019 @default.
• W2022709201 countsByYear W20227092012020 @default.
• W2022709201 countsByYear W20227092012022 @default.
• W2022709201 crossrefType "journal-article" @default.
• W2022709201 hasAuthorship W2022709201A5003905939 @default.
• W2022709201 hasAuthorship W2022709201A5006987355 @default.
• W2022709201 hasAuthorship W2022709201A5012693175 @default.
• W2022709201 hasAuthorship W2022709201A5029398579 @default.
• W2022709201 hasAuthorship W2022709201A5034618391 @default.
• W2022709201 hasAuthorship W2022709201A5050833679 @default.
• W2022709201 hasAuthorship W2022709201A5077996407 @default.
• W2022709201 hasConcept C126322002 @default.
• W2022709201 hasConcept C203014093 @default.
• W2022709201 hasConcept C2522874641 @default.
• W2022709201 hasConcept C2775940106 @default.
• W2022709201 hasConcept C2776694085 @default.
• W2022709201 hasConcept C2777382497 @default.
• W2022709201 hasConcept C2777408962 @default.
• W2022709201 hasConcept C2777410769 @default.
• W2022709201 hasConcept C2777869810 @default.
• W2022709201 hasConcept C2780593183 @default.
• W2022709201 hasConcept C2911091166 @default.
• W2022709201 hasConcept C71924100 @default.
• W2022709201 hasConcept C90924648 @default.
• W2022709201 hasConceptScore W2022709201C126322002 @default.
• W2022709201 hasConceptScore W2022709201C203014093 @default.
• W2022709201 hasConceptScore W2022709201C2522874641 @default.
• W2022709201 hasConceptScore W2022709201C2775940106 @default.
• W2022709201 hasConceptScore W2022709201C2776694085 @default.
• W2022709201 hasConceptScore W2022709201C2777382497 @default.
• W2022709201 hasConceptScore W2022709201C2777408962 @default.
• W2022709201 hasConceptScore W2022709201C2777410769 @default.
• W2022709201 hasConceptScore W2022709201C2777869810 @default.
• W2022709201 hasConceptScore W2022709201C2780593183 @default.
• W2022709201 hasConceptScore W2022709201C2911091166 @default.
• W2022709201 hasConceptScore W2022709201C71924100 @default.
• W2022709201 hasConceptScore W2022709201C90924648 @default.
• W2022709201 hasIssue "15" @default.
• W2022709201 hasLocation W20227092011 @default.
• W2022709201 hasLocation W20227092012 @default.
• W2022709201 hasOpenAccess W2022709201 @default.
• W2022709201 hasPrimaryLocation W20227092011 @default.
• W2022709201 hasRelatedWork W1516348686 @default.
• W2022709201 hasRelatedWork W1556816728 @default.
• W2022709201 hasRelatedWork W1912024884 @default.
• W2022709201 hasRelatedWork W2006701618 @default.

• next